Current Controversies in Lupus Anticoagulant Detection
AbstractAntiphospholipid syndrome is an autoimmune, acquired thrombophilia diagnosed when vascular thrombosis or pregnancy morbidity are accompanied by persistent antiphospholipid antibodies. Lupus anticoagulants (LA) are one of the criteria antibodies but calibration plasmas are unavailable and they are detected by inference based on antibody behaviour in a medley of coagulation-based assays. Elevated screening tests suggest the presence of a LA, which is confirmed with mixing tests to evidence inhibition and confirmatory tests to demonstrate phospholipid-dependence. At least two screening tests of different principle must be used to account for antibody heterogeneity and controversy exists on whether assays, in addition to dilute Russell’s viper venom time and activated partial thromboplastin time, should be employed. A variety of approaches to raw data manipulation and interpretation attract debate, as does inclusion or exclusion of mixing studies in circumstances where the presence of a LA is already evident from other results. Therapeutic anticoagulation compromises coagulation-based assays but careful data interpretation and use of alternative reagents can detect or exclude LA in specific circumstances, and this aspect of LA detection continues to evolve. This review focuses on the main areas of debate in LA detection. View Full-Text
Share & Cite This Article
Moore, G.W. Current Controversies in Lupus Anticoagulant Detection. Antibodies 2016, 5, 22.
Moore GW. Current Controversies in Lupus Anticoagulant Detection. Antibodies. 2016; 5(4):22.Chicago/Turabian Style
Moore, Gary W. 2016. "Current Controversies in Lupus Anticoagulant Detection." Antibodies 5, no. 4: 22.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.